SEC Form 4 · accession 0001179110-15-004557
Allergan plc · AGN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David A Buchen
Officer — See Remarks
Period of report
Mar 5, 2015
Accepted (ET)
Mar 9, 2015 · 6:09 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001578845
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary Shares, par value $0.0001 | Mar 5, 2015 | F | 269 | $295.70 | D | 70,502 | D | |
| Ordinary Shares, par value $0.0001F1 | Mar 5, 2015 | A | 3,996 | $0.00 | A | 74,498 | D | |
| Ordinary Shares, par value $0.0001F2 | Mar 5, 2015 | F | 448 | $295.70 | D | 74,050 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents 3,996 ordinary shares of the Issuer earned based the Issuer's achievement of a pre-established level of Adjusted EBITDA for 2014, subject to time-based vesting as to 25% of the award on each of the first, second, third and fourth anniversaries of the beginning of the 1-year period.
- F2Includes 14,084 restricted share units.
Remarks
The Reporting Person is Executive Vice President, Commercial, North American Generics and International of Actavis plc.